ABAyman Ibrahim Baess

Ayman Ibrahim Baess

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ayman Ibrahim Baess has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative assessment of the role of the dynamic contrast-enhanced CT versus PET-CT in characterization of suspicious lung lesions: a pathologic correlated prospective study with ROC analysis

    by Nooraldeen Alsamahi, Adel Rizk, Abdelaziz Elnekeidy, Ayman Ibrahim Baess, Mohamed Ahmed Mohamed Meheissen, Ahmed Samir

    Background: The positron emission tomography–computed tomography (PET-CT) is the cornerstone in oncologic imaging because of its high sensitivity. However, its specificity is largely compromised by the false-positive uptake in benign infectious and inflammatory conditions. The dynamic contrast-enhanced computed tomography (DCE-CT) is a promising imaging technique that can eventually provide insight into the tumor vascularity and angiogenesis through quantification of tumor perfusion parameters like peak enhancement, net enhancement (wash-in), absolute loss of enhancement (wash-out), as well as the time–intensity curve morphology. Aim of the work : To compare the efficacy and accuracy of DCE-CT versus PET-CT in the characterization of suspicious lung lesions using clinico-laboratory correlation, pathological verification, and follow-up, as well as receiver-operating characteristics (ROC) statistical analysis. Results: Forty patients with indeterminate pulmonary lesions were prospectively enrolled in this study during the period between September/2023 and January/2026. All patients underwent both DCE-CT and PET-CT examinations. Automatic calculations of relevant cutoff values were encountered; then, the ROC analyses and the tests of accuracy were applied. The study was conducted by four expert radiologists, single oncologist, and a single pulmonologist. Peak enhancement : At the initially used “40 HU” value, positive statistical significance was encountered ( p value = 0.003). The area under the ROC curve (AUC) was 0.74, 95% CI [0.57, 0.92], SE = 0.09, p = 0.006. At the estimated “50 HU” threshold, the performance was statistically better. Net enhancement/wash-in : At the initially used “25 HU” value, positive statistical significance was encountered ( p value = < 0.0001). The area under the ROC curve (AUC) was 0.83, 95% CI [0.68, 0.99], SE = 0.08, p < 0.001. At the estimated “23 HU” threshold, the performance was statistically better. Final curve : Type I curve was established in 95% of malignant lesions. On the other hand, type II and III curves were established in 78% and 11% of non-malignant lesions. Positive statistical significance was encountered ( p value = < 0.0001). The overall accuracy of the DCE-CT curve was higher than that of PET-CT SUV (92.5% compared to 80%), with much higher specificity; however, the sensitivity of the DCE-CT is lower. Conclusions: The DCE-CT constitutes a reliable, cost-effective, and widely available alternative for the characterization of the suspicious pulmonary lesions. Quantitative perfusion parameters, particularly wash-in, wash-out, and curve-type analysis, can serve as valuable indicators of malignancy and improve diagnostic confidence in indeterminate cases. Integrating both modalities may yield a more holistic diagnostic model to enhance precision in lung cancer detection and management.

  • Alternations in miR-155 and miR-200 serum levels can serve as biomarkers for COVID-19 in the post-mass vaccination era

    by Aliaa Aboulela, Mona Taha, Abeer Ghazal, Ayman Baess, Amel Elsheredy

    Background Mass vaccination and natural immunity reduced the severity of COVID-19 cases. SARS-CoV-2 ongoing genome variations imply the use of confirmatory serologic biomarkers besides PCR for reliable diagnosis. MicroRNA molecules are intrinsic components of the innate immune system. The expression of miR155-5p and miR200c-3p was previously correlated with SARS-CoV-2 pathogenesis. This case-control study was conducted during the third peak of the COVID-19 pandemic in Egypt and aimed to calculate the accuracy of miR155-5p and miR200c-3p as biomarkers for COVID-19. Methods and results Thirty out of 400 COVID-19 patients at a main University hospital in Alexandria were included in the study along with 20 age-matched healthy controls. Plasma samples were collected for total and differential CBC. Relative quantitation of miR155-5p and miR200c-3p expression from WBCs was done by RT-qPCR. The expression of miR155-5p and miR200c-3p was positively correlated and was significantly downregulated in COVID-19 patients compared to the healthy control group (p ˂ 0.005). Both miR155-5p and miR200c-3p were of 76% and 74% accuracy as diagnostic biomarkers of COVID-19, respectively. Regarding the differentiation between mild and moderate cases, their accuracy was 80% and 70%, respectively. Conclusions miR155-5p and miR200c-3p expression can be used to confirm the diagnosis of COVID-19 and discriminate between mild and moderate cases, with a moderate degree of accuracy.


  • Open Access

    Efficacy and safety of inhaled heparin in asthmatic and chronic obstructive pulmonary disease patients: a systematic review and a meta-analysis

    by Rasha Ashmawy, Adel Zaki, Ayman Baess, Iman El Sayed

    Asthma and chronic obstructive pulmonary disease (COPD) are prevalent chronic respiratory disorders that cause significant morbidity and mortality. Some studies evaluated the use of inhaled unfractionated heparin (UFH) in the treatment of asthma and COPD. We aimed to synthesize the available evidence for the efficacy and safety of inhaled heparin in improving lung functions among asthmatic and COPD patients. A comprehensive search was performed using Pubmed, Embase, EBSCO, Scopus, Web of Science, Cochrane CENTRAL, WHO Clinical trials, clinicaltrials.gov, Iranian Clinical trials, Google Scholar, Research Gate, ProQuest Thesis, OVID, and medRxiv databases. Two independent reviewers included all pertinent articles according to PRISMA guidelines, and extract data independently. The two reviewers checked the quality of studies using the ROB2 tool. To determine the pooled effect estimate of the efficacy and safety of inhaled heparin, a meta-analysis was carried out using the R programming language. Publication bias was evaluated using Egger’s regression test. The heterogeneity was explained using a meta-regression, and the quality of evidence was assessed by the GRADE approach. Twenty-six studies with a total of 581 patients were included in the qualitative analysis and 16 in the meta-analysis. The primary outcome was treatment success (improvement of lung function) that was measured by standardized mean differences (SMD) of the forced expiratory volume per second (FEV1) either per ml or percentage. Heparin has a large effect on both FEV1% and FEV1 ml when compared to the control group (SMD 2.7, 95% CI 1.00; 4.39; GRADE high, SMD 2.12, 95% CI − 1.49; 5.72: GRADE moderate, respectively). Secondary outcomes are other lung functions improving parameters such as PC20 (SMD 0.91, 95% CI − 0.15; 1.96). Meta-regression and subgroup analysis show that heparin type, dose, year of publication, study design, and quality of studies had a substantial effect. Regarding safety, inhaled heparin showed a good coagulation profile and mild tolerable side effects. Inhaled heparin showed improvement in lung functions either alone or when added to standard care. More large parallel RCTs are needed including COPD patients, children, and other types, and stages of asthmatic patients.


  • Open Access

    A stepwise multi-disciplinary algorithm for diagnosis of fibrosing lung diseases contributing MDCT, MRI, and PET/CT: a study on 250 patients using significance and validation analyses

    by Ahmed Samir, Mohamed Hossameldin Khalifa, Ayman Ibrahim Baess, Rania Ahmed Sweed, Ahmed Mohamed Abougabal, Aya Abdel Galeel

    Background: The new guidelines limited the use of lung biopsy in the evaluation of lung fibrosis because of its hazards. The differential diagnosis of interstitial pulmonary fibrosis (IPF) or usual interstitial pneumonia (UIP) is challenging because of overlapping multi-detector computed tomography (MDCT) morphologic features between interstitial and non-interstitial fibrosing lung diseases. Scar carcinoma is a serious complication that needs to be excluded in certain conditions. Aim of the work: To achieve a multi-disciplinary algorithm for the diagnosis of fibrosing lung diseases to limit the need for lung biopsy by combining the clinico-laboratory and radiological roles. Results: This study included two major steps. The first step (prevalence/significance analysis of the contributing parameters for the diagnosis of fibrosing lung diseases) was retrospectively conducted on 150 patients pathologically proved with fibrosing lung disease during the period between January/2016 and April/2018. Based on a P-value < 0.001, honeycombing bronchiectasis was significant to IPF. Basal traction bronchiectasis/bronchiolectasis was relevant to fibrosing non-specific interstitial pneumonia (NSIP). "Head cheese" CT-sign, history of allergen exposure, blood eosinophilia, and broncho-alveolar lavage (BAL) lymphocytosis were relevant to chronic hypersensitivity pneumonitis (HP). Upper peripheral lung fibrosis was significant to pulmonary tuberculosis (TB) and pleuroparenchymal fibroelastosis (PPFE). Cavitations, tree-in-bud, and calcific nodules were relevant to TB, while the "platy-thorax" CT-sign was relevant to PPFE. The upper peribronchovascular fibrosis was relevant to sarcoidosis and progressive massive fibrosis (PMF); additionally, calcific changes were relevant to PMF. Bright T2-signal, diffusion weighted-image (DWI) restriction in magnetic-resonance imaging (MRI), and high standardized uptake value (SUV) in positron emission tomography (PET-CT) were significant to scar carcinoma. Eventually, an algorithm was created. The second step (validation analysis) prospectively targeted 100 patients initially diagnosed with lung fibrosis during the period from June/2018 to June/2022. It revealed 83.3–100% sensitivity, 96.3–100% specificity, 85.7–100% PPV, 96.4–100% NPV, and 96–100% accuracy, with balanced accuracy = 0.91–1. Four consulting radiologists and two consulting pulmonologists participated in this study. Conclusions: A valid stepwise multi-disciplinary algorithm was proposed for the diagnosis of interstitial and non-interstitial fibrosing lung diseases to limit the need and hazards of lung biopsy. It contributed significant clinico-laboratory data, MDCT features, T2-WI and DWI-MRI findings as well as PET/CT results.

  • Open Access

    Splenomegaly versus pathological lung volume during COVID-19 infection with or without cytokine storm; a linear regression analysis using CT volumetry

    by Ahmed Samir, Heba Said Gharraf, Ayman Ibrahim Baess, Rania Ahmed Sweed, Khaled Matrawy, Mats Geijer, Adel Shalabi, Yasmine Tarek

    Background: Due to the paucity of scientific evidence, it is unclear among pulmonologists and physicians in critical care units if and when splenomegaly in novel coronavirus disease (2019) (COVID-19) patients is worrisome. This study aims to evaluate the significance of splenic volume during COVID-19 infection with or without cytokine storm and correlates splenic volume to the volume of pathological lung changes through linear regression analysis. Results: A retrospective study collected 509 polymerase chain reaction proved COVID-19 patients (399 males, 110 females; mean age 48 years, age range 24–78 years) between June and November 2021, without a history of splenic pathology. A control group of age and sex-matched 509 healthy subjects was used and analyzed according to the splenic volume. Five consulting radiologists evaluated initial and follow-up computed tomography (CT) examinations using lung CT volumetry and splenic volume calculation in consensus. Three consulting pulmonologists correlated the severity of clinical and laboratory findings, including oxygen requirements and interleukin-6 (IL-6) levels. The T test results for comparison between the COVID-19 patients and the healthy subjects control group regarding the splenic volume were significant (T value was − 4.731452 and p value was 0.00002). There was no significant correlation between the severity of the disease and normal-sized spleen (26% of patients, p = 0.916) or splenomegaly (24% of patients, p = 0.579). On the other hand, all patients with a small spleen or progressive splenomegaly during serial follow-up imaging had clinically severe disease with a statistically significant correlation (p = 0.017 and 0.003, respectively). Ninety-seven percent of patients with clinically mild disease and splenomegaly had 0–20% lung involvement (CT-severity score 1) while all patients with clinically severe disease and splenomegaly had 27–73% lung involvement (CT-severity score 2 and 3) (r = 0.305, p = 0.030). Conclusions: Splenomegaly is a non-specific sign that may be found during mild and severe COVID-19 infection, it was not statistically correlated with the clinical severity and a weak positive relationship was found between the splenic size and the CT-severity score of the pathological lung volume. On the other hand, the presence of splenic atrophy or progressive splenomegaly was correlated with severe COVID-19 presentation and “cytokine storm”. Therefore, the splenic volume changes should not be overlooked in COVID-19 serial CT examinations, particularly in severe or critically ill patients with cytokine storms.


  • Open Access

    Thymus CT-grading and rebound hyperplasia during COVID-19 infection: a CT volumetric study with multivariate linear regression analysis

    by Ahmed Samir, Rim Aly Bastawi, Ayman Ibrahim Baess, Rania Ahmed Sweed, Omnia Ezz Eldin

    Background: The importance of thymic CT-grading and presence of thymic rebound hyperplasia during COVID-19 infection were only investigated in a few studies. This multivariate study aims to evaluate the relation between thymus CT-grading and rebound during COVID-19 infection and the following: (1) the patients' age, (2) the patients' blood lymphocytic count, (3) the CT-volumetry of the diseased lung parenchyma, (4) the patient's clinical course and prognosis, and finally (5) the final radiological diagnosis. Results: Multicenter retrospective analyses were conducted between March and June 2021 on 325 adult COVID-19 patients with positive PCR results and negative history of malignant or autoimmune diseases. They included 186 males and 139 females (57.2%:42.8%). Their mean age was 40.42 years ± 14.531 SD. Three consulting radiologists performed CT-grading of the thymus gland (grade 0–3) and CT-severity scoring (CT-SS) of the pathological lung changes in consensus. Two consulting pulmonologists correlated the clinical severity and blood lymphocytic count. Pearson correlation coefficient (r) and linear regression analyses were statistically utilized. Sub-involuted thymus (with CT-grade 0:2) was detected in 42/325 patients (12.9%); all of them had a mild clinical course and low CT-SS (0–1). Thymic rebound hyperplasia was the only positive CT-finding in 15/325 patients (4.6%) without pathological lung changes. A weak positive significant correlation was proved between thymic grade and patient's age, clinical course, and CT-SS (r = 0.217, 0.163, and 0.352 with p ≤ 0.0001, < 0.0001, and 0.002, respectively). A weak negative significant correlation was found between thymic grade and lymphocytic count (r = − 0.343 and p ≤ 0.0001). A strong positive significant correlation was encountered between clinical severity against patients' age and CT-SS (r = 0.616 and 0.803 with p ≤ 0.0001). Conclusions: The presence of sub-involuted thymus or thymic rebound should not be radiologically overlooked in COVID-19 patients. During COVID-19 infection, the presence of sub-involuted thymus with low CT-grading (0–2) was correlated with young age groups, low CT-severity scoring, mild clinical course, and better prognosis (good prognostic factor). It was seldom seen in old hospitalized patients. Atypically, it was also correlated with normal lymphocytic count or even lymphocytosis. The thymic rebound could be the only positive CT-finding even during the absence of lung involvement.


  • Open Access

    COVID-19 in Egypt after a year: the first and second pandemic waves from the radiological point of view; multi-center comparative study on 2000 patients

    by Ahmed Samir, Amr Magdy Elabd, Walid Mohamed, Ayman Ibrahim Baess, Rania Ahmed Sweed, Mohamed Saied Abdelgawad

    Background: One year has passed since the announcement of COVID-19 as a pandemic and two waves had already stricken Egypt. The authors witnessed several atypical radiological features through the second pandemic wave, either early at the active infective stage or delayed at the post-infectious convalescent period. They believed every radiologist should be familiar with these features. Therefore, they performed this comparative study on 2000 Egyptian patients using multi-slice computed tomography (MSCT) to highlight the radiological differences between the first and second pandemic waves and correlate them to the clinical status. Results: This random multi-center comparative study was retrospectively conducted on 2000 COVID-19 Egyptian patients; 1000 patients were registered at the first pandemic wave from April 2020 till September 2020, while the other 1000 patients were registered at the second pandemic wave from October 2020 till March 2020. Follow up CT examinations were performed for 49 and 122 patients through the first and second pandemic waves respectively. MSCT examinations were carefully evaluated by four expert consulting radiologists who came to a consensus. Meanwhile, the correlation with the clinical outcome was performed by two consulting pulmonologists. During the second pandemic wave, the prevalence rate of the “crazy-paving” pattern had significantly increased by 1.3 times (P value = 0.002). Additionally, the prevalence rate of the “air-bubble” sign had significantly increased by 1.9 times (P value = 0.02). Similarly, the presence of enlarged mediastinal lymph nodes (> 1 cm in short-axis diameter) had significantly increased by 1.7 times (P value = 0.036). Furthermore, the prevalence rate of pericardial effusion had significantly increased by 2.5 times (P value = 0.003). The above-mentioned signs were correlated to increased clinical severity and higher rates of hospitalization. Unexpectedly, other atypical radiological signs were only encountered through the second pandemic wave, including bronchiectatic changes (2.5%), “head-cheese” pattern (0.8%), cavitation (0.5%), and “bulls-eye” sign (0.2%). The prevalence rate of post-COVID fibrosis had doubled through the second wave but not in a significant way (P value = 0.234). Secondary fungal infection was only encountered throughout the second pandemic wave in four patients. COVID-19 reinfection was encountered in a single patient only during the second pandemic wave. Conclusion: After 1 year from the announcement of COVID-19 as a pandemic, the radiological presentation of COVID-19 patients showed some significant differences between its first and second waves.


  • Open Access

    COVID-19-induced vascular angiopathy: CTPA signs in critically ill patients other than acute pulmonary embolism and high-lung opacity scores

    by Mohamed Hossameldin Khalifa, Ahmed Samir, Ayman Ibrahim Baess, Sara Samy Hendawi

    Background: Vascular angiopathy is suggested to be the major cause of silent hypoxia among COVID-19 patients without severe parenchymal involvement. However, pulmonologists and clinicians in intensive care units become confused when they encounter acute respiratory deterioration with neither severe parenchymal lung involvement nor acute pulmonary embolism. Other radiological vascular signs might solve this confusion. This study investigated otherindirect vascular angiopathy signson CT pulmonary angiography (CTPA) and involved a novel statistical analysis that was performed to determine the significance of associations between these signs and the CT opacity score of the pathological lung volume, which is calculated by an artificial intelligence system.Results: The study was conducted retrospectively, during September and October 2020, on73 patients with critical COVID-19who were admitted to the ICU with progressive dyspnea and low O2saturation on room air (PaO2< 93%). They included 53 males and 20 females (73%:27%), and their age ranged from 18 to 88 years (mean ± SD=53.3 ± 13.5).CT-pulmonary angiographywas performed for all patients, and anartificial intelligence systemwas utilized to quantitatively assess the diseased lung volume. The radiological data were analyzed by three expert consultant radiologists to reach consensus. A low CT opacity score (≤10) was found in 18 patients (24.7%), while a high CT opacity score (>10) was found in 55 patients (75.3%). Pulmonary embolism was found in 24 patients (32.9%); three of them had low CT opacity scores. Four other indirect vasculopathy CTPA signs were identified: (1) pulmonary vascular enlargement (57 patients—78.1%), (2) pulmonary hypertension (14 patients—19.2%), (3) vascular tree-in-bud pattern (10 patients—13.7%), and (4) pulmonary infarction (three patients—4.1%). There were no significant associations between these signs and the CT opacity score (0.3205–0.7551, all >0.05). Furthermore, both pulmonary vascular enlargement and the vascular tree-in-bud sign were found in patients without pulmonary embolism and low CT-severity scores (13/15–86.7% and 2/15–13.3%, respectively).Conclusion: Pulmonary vascular enlargement or, less commonly, vascular tree-in-bud pattern are both indirect vascular angiopathy signs on CTPA that can explain the respiratory deterioration which complicates COVID-19 in the absence of severe parenchymal involvement or acute pulmonary embolism.


  • Open Access

    COVID-19 clinico-radiological mismatch: a proposal for a novel combined morphologic/volumetric CT severity score with blinded validation

    by Ahmed Samir, Abdelaziz Elnekeidy, Heba Said Gharraf, Ayman Ibrahim Baess, Tarek El-Diasty, Dina Altarawy

    Background: Some COVID-19 patients with similar quantitative CT measurements had variable clinical presentation and outcome. The absence of reasonable clinical explanations, such as pre-existing comorbidities or vascular complications, adds to the confusion. The authors believed that neglecting the impact of certain severe morphologic features could be an alternative radiological explanation. This study aims to optimize the initial CT staging of COVID-19 and propose a new combined morphologic/volumetric CT severity index (CTSI) to solve this clinico-radiological mismatch. Results: This multi-center study included two major steps. The first step of the study entailed a standardized combined morphologic/volumetric CT severity analyses to propose a new optimized CTSI. This was conducted retrospectively during the period from June till September 2020. It included 379 acutely symptomatic COVID-19 patients. They were clinically classified according to their oxygen saturation and respiratory therapeutic requirements into three groups: group A (mild 298/79%), group B (borderline severity 57/15%), and group C (severe/critical 24/6%). The morphologic and volumetric assessment of their HRCT was analyzed according to severity, by two consultant radiologists in consensus. A new 25 point-CTSI has been created, combining eight morphological CT patterns [M1:M8; 8 points] and four grades of volumetric scores [S1:S4; 17 points]. The addition of the M5 pattern (air bubble sign), M6 pattern (early fibrosis and architectural distortion), or M7 pattern (crazy-paving) proved to increase the clinical severity. The second step of the study entailed a standardized blinded/independent validation analysis for the proposed CTSI. This was prospectively conducted on other 132 patients during October 2020 and independently performed by other two consultant radiologists. Validation results reached 80.2% sensitivity, 91.8% specificity, AUROC-curve = 0.8356, and 90.9% accuracy. Conclusion: A new optimized CTSI with accepted validation is proposed for initial staging of COVID-19 patients, using combined morphologic/volumetric assessment instead of the quantitative assessment alone. It could solve the clinico-radiological mismatch among patients with similar quantitative CT results and variable clinical presentation during the absence of pre-existing comorbidities or vascular complications.


  • Open Access

    Modified thoracoscopic pleural cryo-biopsy in diagnosis of exudative pleural effusion of undetermined etiology

    by Ayman Ibrahim Baess, Essam Gouda Hassanein, Mohamed Al Saeed Emara, Heba Ahmed Eshmawey

    Background: Rigid thoracoscopy is the gold standard tool for diagnosing exudative pleural effusion, but sometimes it is difficult to obtain sufficient biopsies using the conventional forceps. This study evaluated the efficacy, safety, and diagnostic value of a modified technique using cryoprobe to obtain pleural biopsies during thoracoscopy. Results: This is a single-center prospective study in patients that underwent rigid thoracoscopy using conventional rigid forceps followed by a cryoprobe at the same setting after injection of subpleural mixture of adrenaline and xylocaine. Biopsies were reviewed by an independent pathologist; any complications were recorded, and all patients were followed-up post-procedure. Twenty-four patients (12 males; mean age was 56 ± 15.1years) were included. The diagnostic yield of both rigid forceps biopsy (RFB) and cryoprobe biopsy (CPB) was 100%. CPB had more surface area than RFB with no difference regarding largest diameter (p = 0.064). RFB and CPB had similar results regarding presence of fat cells. CPB had much less crushed cells than RFB with better tissue preservation (p = 0.004). No significant complications were reported. Conclusions: The modified cryoprobe biopsy is a highly effective and safe way for obtaining pleural biopsy besides affording good quality and size of the biopsy especially in thick firmly adherent pleura.